DataMeds AI (MEDS) Gross Margin (2024 - 2026)

DataMeds AI (MEDS) has reported Gross Margin for 3 consecutive years, with 10.91% the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 454.0% year-over-year to 10.91%; the trailing twelve-month figure through Mar 2026 stood at 49.51% (down 5800.0% YoY), and the FY2025 full-year result was 27.54%, down 3729.0% from the prior year.
• Gross Margin improved to 10.91% in Q1 2026 per MEDS's latest filing, from 470.23% in the prior quarter.
• Across five years, Gross Margin topped out at 10.91% in Q1 2026 and bottomed at 470.23% in Q4 2025.
• Historically, Gross Margin has averaged 53.17% across 3 years, with a median of 7.08% in 2025.
• The widest YoY moves for Gross Margin: up 1235 bps in 2025, down 48029 bps in 2025.
• Over 3 years, Gross Margin stood at 10.06% in 2024, then sank by 4774 bps to 470.23% in 2025, then soared by 102 bps to 10.91% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 10.91%, 470.23%, and 7.67% for Q1 2026, Q4 2025, and Q3 2025 respectively.